ICH = 2 Years after last approval based on study [Regulatives / Guidelines]

posted by Ohlbe – France, 2020-09-01 11:03 (753 d 13:47 ago) – Posting: # 21906
Views: 1,652

Dear Brus,

» 2 Years for ICH? Where did you find that?

In ICH E6 (GCP), § 4.9.5:

Essential documents should be retained until at least 2-years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2-years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period however if required by the applicable regulatory requirements or by an agreement with the sponsor.

Cave: not 2 years after the end of the study, but 2 years after the last approval based on that study.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
22,385 posts in 4,684 threads, 1,594 registered users;
online 5 (0 registered, 5 guests [including 3 identified bots]).
Forum time: Sunday 00:51 CEST (Europe/Vienna)

You really don’t know what you don’t know until you write about it.
Then, everyone knows what you don’t know.    Rod Machado

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5